In a ‘binge’ model of limited access to ethanol, pioglitazone had no effect (Figure 2 A; Supplemental Figure 4 A,B,C; Supplemental Table 4), but fenofibrate strongly reduced ethanol intake and preference without changing total fluid intake (Figure 2 B; Supplemental Figure 4 D,E,F; Supplemental Table 4). GW0742 did not change ethanol intake (Figure 2 C; Supplemental Figure 4 G,H,I; Supplemental Table 4). Tesaglitazar profoundly reduced ethanol intake and preference and also increased total fluid intake (Figure 2 D; Supplemental Figure 4 J,K,L; Supplemental Table 4). Bezafibrate (75 mg/kg) modestly reduced ethanol intake and preference without changing total fluid intake (Figure 2 E; Supplemental Figure 4 M,N,O; Supplemental Table 4). Thus, in both tests, activation of α and γ PPARs (but not δ) reduced alcohol intake and preference in mice genetically predisposed to drink high levels of alcohol. No changes in body weight were observed in control (saline) or drug treatment groups in either drinking test (data not shown).
